The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.00
Bid: 13.50
Ask: 14.50
Change: -0.50 (-3.45%)
Spread: 1.00 (7.407%)
Open: 14.50
High: 14.50
Low: 14.00
Prev. Close: 14.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director dealings: Angle CEO, finance chief join capital raise

Tue, 19th Jul 2022 16:35

(Sharecast News) - Liquid biopsy specialist Angle had two entries on the list of director buys on Tuesday, after its chief executive and chief financial officers invested in shares.

The AIM-traded firm said CEO Andrew Newland bought 125,000 shares for 80p each, spending a total of £100,000.

At the same time, its CFO Ian Griffiths spent £30,000 on 37,500 shares, also at 80p apiece.

Both transactions took place off-market, as part of the company's capital raise of £20.13m through a placing, retail offer and management subscription, announced on Friday.

Reporting by Josh White at Sharecast.com.

Top Director Buys

Alphawave Ip Group (AWE)

Director name: Sutardja,Sehat

Amount purchased: 538,867 @ 121.84p

Value: £656,555.55

Angle (AGL)

Director name: Newland,Andrew D

Amount purchased: 125,000 @ 80.00p

Value: £100,000.00

Fevertree Drinks (FEVR)

Director name: Havelock,Kevin

Amount purchased: 10,000 @ 887.70p

Value: £88,770.00

Fevertree Drinks (FEVR)

Director name: Havelock,Kevin

Amount purchased: 10,000 @ 871.54p

Value: £87,154.00

Fevertree Drinks (FEVR)

Director name: Havelock,Kevin

Amount purchased: 4,000 @ 877.10p

Value: £35,084.00

Angle (AGL)

Director name: Griffiths,Ian F

Amount purchased: 37,500 @ 80.00p

Value: £30,000.00

Fevertree Drinks (FEVR)

Director name: Havelock,Kevin

Amount purchased: 2,816 @ 887.54p

Value: £24,993.13

Schroder British Opportunities Trust (SBO)

Director name: Bartlett,Diana Dyer

Amount purchased: 26,345 @ 75.50p

Value: £19,890.47

Fevertree Drinks (FEVR)

Director name: Havelock,Kevin

Amount purchased: 2,000 @ 960.00p

Value: £19,200.00

Fevertree Drinks (FEVR)

Director name: Havelock,Kevin

Amount purchased: 2,000 @ 956.58p

Value: £19,131.60

More Acquisitions (TMOR)

Director name: McIllree ,Roderick

Amount purchased: 2,000,000 @ 0.95p

Value: £18,900.00

Schroder British Opportunities Trust (SBO)

Director name: England,Neil

Amount purchased: 25,000 @ 75.15p

Value: £18,787.50

Audioboom Group (BOOM)

Director name: Last,Stuart

Amount purchased: 1,218 @ 820.00p

Value: £9,987.60

Audioboom Group (BOOM)

Director name: Last,Stuart

Amount purchased: 1,410 @ 708.25p

Value: £9,986.32

Audioboom Group (BOOM)

Director name: Tobin,Michael

Amount purchased: 1,117 @ 850.00p

Value: £9,494.50

Genflow Biosciences (GENF)

Director name: Leire,Eric

Amount purchased: 308,999 @ 3.03p

Value: £9,362.67

Velocys Plc (VLS)

Director name: Sanderson,Philip

Amount purchased: 200,000 @ 4.30p

Value: £8,600.00

Time Finance (TIME)

Director name: Roberts ,James

Amount purchased: 26,972 @ 18.50p

Value: £4,989.82

Schroder British Opportunities Trust (SBO)

Director name: Jenkinson,Tim

Amount purchased: 6,609 @ 75.15p

Value: £4,966.53

Schroder British Opportunities Trust (SBO)

Director name: OBE,Christopher Keljik,

Amount purchased: 6,577 @ 75.50p

Value: £4,965.50

Time Finance (TIME)

Director name: Telling,Julian

Amount purchased: 26,000 @ 18.85p

Value: £4,901.00

Coca-cola Hbc Ag (cdi) (CCH)

Director name: Bogdanovic,Zoran

Amount purchased: 218 @ 1,956.75p

Value: £4,265.71

Time Finance (TIME)

Director name: Raynes ,Tanya

Amount purchased: 21,156 @ 18.85p

Value: £3,987.91

Bae Systems (BA.)

Director name: Woodburn,Charles

Amount purchased: 19 @ 804.96p

Value: £152.94

Bae Systems (BA.)

Director name: Greve,Brad

Amount purchased: 19 @ 804.96p

Value: £152.94

(HWG)

Director name: Birch,Chris

Amount purchased: 107 @ 140.00p

Value: £149.80

(HWG)

Director name: Patmore,Katerina

Amount purchased: 107 @ 140.00p

Value: £149.80

(HWG)

Director name: Shillaw,Lynda

Amount purchased: 107 @ 140.00p

Value: £149.80

More News
24 Apr 2024 17:06

CORRECT: No record close for FTSE 100; mixed trade in US

(Correcting day of the week in the opening sentence.)

Read more
24 Apr 2024 17:00

LONDON MARKET CLOSE: No record close for FTSE 100; mixed trade in US

(Alliance News) - Stock prices in London closed lower on Thursday, with the FTSE 100's recent rally taking a pause for breath, but not after hitting another record high.

Read more
24 Apr 2024 10:32

Angle shares jump on supplier agreement with with AstraZeneca

(Alliance News) - Angle PLC shares rose on Wednesday, after it signed a contract with AstraZeneca PLC.

Read more
24 Apr 2024 10:10

AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
22 Apr 2024 16:52

IN BRIEF: Angle granted patents in US and Europe for Cellkeep slide

Angle PLC - Surrey-based medical diagnostics provider - Says it has been granted a European and US patent for its CellKeep slide. "We are delighted to have secured intellectual property rights for our proprietary CellKeep slide in two major jurisdictions....This is a significant technology advancement for the [circulating tumor cell] liquid biopsy field and another step towards enabling biomarker-guided precision medicine for people with cancer," says Chief Executive Officer Andrew Newland. The CellKeep slide was developed by Angle to reduce cell loss during the transfer of CTCs to the microscope slide and to protect the morphology of the harvested cells.

Read more
22 Apr 2024 06:59

Angle granted European patent for CellKeep, US patent imminent

(Sharecast News) - Liquid biopsy specialist Angle announced on Monday that it has received a European patent for its 'CellKeep' slide, as it anticipated the imminent grant of an equivalent US patent application.

Read more
22 Jan 2024 18:03

IN BRIEF: Angle highlights supportive data for DNA analysis tool

Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.

Read more
4 Jan 2024 16:54

LONDON MARKET CLOSE: Stocks up ahead of US nonfarm payrolls

(Alliance News) - Stock prices in London closed higher on Thursday, as investors eye the latest US non-farms data.

Read more
4 Jan 2024 12:19

Angle shares soar following "breakthrough" cancer diagnostics results

(Alliance News) - Angle PLC on Thursday said that "breakthrough results" from its latest blood sample cancer trials would allow it to expand its product sales and pharma services.

Read more
4 Jan 2024 12:09

LONDON MARKET MIDDAY: Retailers Next and JD Sports bookend FTSE 100

(Alliance News) - Stock prices in London were slightly higher at midday on Thursday, with the FTSE 100 looking set to snap the two-day losing streak it suffered at the start of the year.

Read more
4 Jan 2024 10:43

AIM WINNERS & LOSERS: Angle soars on clinical tests; Likewise sales up

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
4 Jan 2024 08:58

LONDON MARKET OPEN: Next leads buoyant FTSE 100 amid services PMIs

(Alliance News) - Stock prices in London opened up on Thursday, amid a slew of services PMI data, including for the UK, while reacting to the latest data from China.

Read more
4 Jan 2024 07:58

Angle receives 'breakthrough results' from DNA molecular analysis

(Sharecast News) - Liquid biopsy company Angle received "breakthrough results" from DNA molecular analysis of cancer patient blood samples on Thursday, sending its shares skywards as a result.

Read more
2 Jan 2024 09:04

Angle locks in $250,000 contract with Eisai

(Sharecast News) - Liquid biopsy company Angle has locked in a $250,000 contract with global pharmaceutical company Eisai to deliver circulating tumour cell analysis in a pilot study.

Read more
2 Jan 2024 08:51

IN BRIEF: Angle teams with Japan's Eisai in breast cancer drug trial

Angle PLC - Surrey, England-based medical diagnostics - Signs contract with Eisai Inc, part of Tokyo-based pharmaceutical firm Eisai Co Ltd. Under the agreement, the two will engage in a pilot study worth USD250,000 to Angle. Angle will provide circulating-tumour-cells analysis using its Portrait HER2 assay to assess the response of breast cancer patients to Eisai's BB-1701 antibody-drug conjugate. BB-1701 targets HER2, a protein that speeds up the growth of breast cancer cells. Success in the phase two pilot study will offer the possibility for multiple follow-up studies.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.